Quell Therapeutics advanced its lead CAR-Treg candidate QEL-005 this week, using the EULAR 2026 Congress in London to showcase new preclinical data and provide an update on its CHILL autoimmune trial. The multinational Phase 1/2 basket study is enrolling patients with refractory rheumatoid arthritis and systemic sclerosis across the U.K., Germany, and Spain, with initial clinical findings targeted for Q1 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company also drew attention to CHILL as a case study for the U.K. advanced therapies ecosystem, highlighting that the Advanced Therapy Investigational Medicinal Product trial was activated in 113 days versus a 150-day target. At The Newcastle Upon Tyne Hospitals NHS Foundation Trust, early engagement and parallel local reviews cut the interval from Local Information Pack to site approval to 36 days.
Quell emphasized that this accelerated start-up reflects close collaboration with the NIHR Clinical Research Facility, NIHR Industry Hub, Newcastle Advanced Therapies, and Northern Alliance ATTC partners. The company positioned this operational execution as evidence of its ability to deliver complex multicenter cell therapy trials efficiently within the U.K. research and regulatory framework.
From a strategic standpoint, participation at a major European rheumatology meeting and recognition within NIHR case studies bolster Quell’s visibility among clinicians, regulators, and potential partners. While CHILL remains in early stages and clinical efficacy data are still pending, the combination of advancing enrollment, compressed activation timelines, and growing ecosystem integration supports the company’s longer-term prospects in autoimmune-focused Treg cell therapies.
Overall, the week underscored Quell Therapeutics’ progress in scaling and de-risking its CHILL program operationally, while reinforcing QEL-005 as a central asset in its drive to secure partnerships and future funding in the competitive cell therapy landscape.